Smart insulin pump takes on diabetes and stomach paralysis

NCT ID NCT07287943

Recruiting now Disease control Sponsor: Viral N. Shah Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the Medtronic 780G automated insulin pump can improve blood sugar control in adults with type 1 diabetes who also have gastroparesis (stomach paralysis). Participants will use the device for three months, and researchers will measure how often blood sugar stays in a healthy range. The trial aims to see if this smart pump can handle the unpredictable digestion caused by gastroparesis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Medtronic 780G automated insulin delivery system (a device that automatically adjusts insulin delivery)
What this could lead to: If it works, this could show that the Medtronic 780G system helps people with both type 1 diabetes and gastroparesis achieve better blood sugar control, potentially reducing complications.
What could go wrong: This is a small, early-stage trial with only 34 participants, so results may not apply to everyone. The device may not work as well in people with gastroparesis due to unpredictable digestion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROPARESIS DUE TO DIABETES MELLITUS TYPE I are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroparesis type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROPARESIS DUE TO DIABETES MELLITUS TYPE I TYPE 1 DIABETES

Contacts and locations

Locations

Indiana University Health, Univeristy hospital
RECRUITING

Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.